First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets remains negative
Q1 FY2026 total assets was $290.58M, compared with $0 a year earlier.
Context
- Total assets increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 330.55M USD
- Year-over-year change
- -25.2%
- 2-year CAGR
- -13.7%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 330.55M | -25.2% |
| FY2024 | 2024-12-31 | 441.89M | -0.5% |
| FY2023 | 2023-12-31 | 444.11M | — |
Total Assets vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 total assets of $290.58M is the 4th highest of the 10 companies compared; the peer median is $198.72M.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | $760.97M | +30.5% | +33.1% | |
| Mar 2026 | $400.37M | -21.7% | +76.8% | |
| Mar 2026 | $329.68M | -21.9% | -15.8% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $290.58M | — | — |
| Jun 2026 | $238.21M | +690.6% | +50.3% | |
| Mar 2026 | $198.72M | +0.3% | -14.3% | |
| Mar 2026 | $189.74M | +824.9% | -42.7% | |
CLYMClimb Bio, Inc. | Mar 2026 | $152.37M | -24.1% | +7.5% |
| Mar 2026 | $146.67M | -9.1% | +22.1% | |
| Jun 2026 | $128.35M | — | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding TRAX) | $198.72M | -4.4% | +14.8% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.